BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...succeeds CFO Sylvia Cheung, who is stepping down. Levitz was SVP, CFO and treasurer of Insulet Corp....
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Bradrick as CFO, a new position. She was VP of strategy and corporate development at Insulet Corp....
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...EVP and general counsel, a newly created position. He was SVP and general counsel at Insulet Corp....
BioCentury | Jan 14, 2017
Finance

JPM jump

...NASDAQ:SGMO) 21% $4.40 Clovis Oncology Inc. (NASDAQ:CLVS) 20% $55.46 PTC Therapeutics Inc. (NASDAQ:PTCT) 19% $15.47 Insulet Corp....
BioCentury | Sep 19, 2016
Financial News

Insulet completes private placement of senior convertible notes

Insulet Corp. (NASDAQ:PODD), Billerica, Mass. Business: Drug delivery, Endocrine/Metabolic Date completed: 2016-09-07 Type: Private placement of senior convertible notes Raised: $300 million Shares outstanding prior: 57.3 million Investor: Institutional investors Note: The notes bear 1.25%...
BioCentury | Dec 30, 2015
Company News

Management tracks

...Aviv:MNKD) hired Duane DeSisto as president and CEO, effective Jan. 5. DeSisto was CEO of Insulet Corp....
BioCentury | Apr 13, 2015
Clinical News

Cenderitide: Completed Phase II enrollment

...0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusion via Insulet’s...
BioCentury | Apr 1, 2015
Company News

Management tracks

...and assistant secretary at Cubist Pharmaceuticals Inc. , which Merck & Co. Inc. (NYSE:MRK) acquired. Insulet Corp....
BioCentury | Mar 9, 2015
Clinical News

Cenderitide: Phase II started

...0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet...
BioCentury | Dec 8, 2014
Clinical News

CSI Glucagon regulatory update

...The room temperature-stable glucagon solution is delivered continuously via OmniPod infusion patch pump technology from Insulet Corp....
Items per page:
1 - 10 of 16
BioCentury | Aug 7, 2020
Management Tracks

First chief diversity officer for Alexion; plus changes at WuXi, Dicerna, Valneva, MeiraGTx, Anika and more

...succeeds CFO Sylvia Cheung, who is stepping down. Levitz was SVP, CFO and treasurer of Insulet Corp....
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Bradrick as CFO, a new position. She was VP of strategy and corporate development at Insulet Corp....
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...EVP and general counsel, a newly created position. He was SVP and general counsel at Insulet Corp....
BioCentury | Jan 14, 2017
Finance

JPM jump

...NASDAQ:SGMO) 21% $4.40 Clovis Oncology Inc. (NASDAQ:CLVS) 20% $55.46 PTC Therapeutics Inc. (NASDAQ:PTCT) 19% $15.47 Insulet Corp....
BioCentury | Sep 19, 2016
Financial News

Insulet completes private placement of senior convertible notes

Insulet Corp. (NASDAQ:PODD), Billerica, Mass. Business: Drug delivery, Endocrine/Metabolic Date completed: 2016-09-07 Type: Private placement of senior convertible notes Raised: $300 million Shares outstanding prior: 57.3 million Investor: Institutional investors Note: The notes bear 1.25%...
BioCentury | Dec 30, 2015
Company News

Management tracks

...Aviv:MNKD) hired Duane DeSisto as president and CEO, effective Jan. 5. DeSisto was CEO of Insulet Corp....
BioCentury | Apr 13, 2015
Clinical News

Cenderitide: Completed Phase II enrollment

...0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusion via Insulet’s...
BioCentury | Apr 1, 2015
Company News

Management tracks

...and assistant secretary at Cubist Pharmaceuticals Inc. , which Merck & Co. Inc. (NYSE:MRK) acquired. Insulet Corp....
BioCentury | Mar 9, 2015
Clinical News

Cenderitide: Phase II started

...0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet...
BioCentury | Dec 8, 2014
Clinical News

CSI Glucagon regulatory update

...The room temperature-stable glucagon solution is delivered continuously via OmniPod infusion patch pump technology from Insulet Corp....
Items per page:
1 - 10 of 16